



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
29 September 2023
13 September 2023

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Andrew Robert Donald Somervell
Fisher & Paykel Healthcare Corporation Limited
Vice President - Products & Technology

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

(a) Options to acquire Ordinary Shares
(b) Ordinary Shares
Beneficial

For that relevant interest

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

(a) 154,649 Options
(b) 98,631 Ordinary Shares
(a) 117,027 Options
(b) 103,490 Ordinary Shares
Andrew Robert Donald Somervell
Andrew Robert Donald Somervell

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Two

Details of transactions requiring disclosure-

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

(a) 26 September 2023
(b) 26 September 2023
(a) Cancellation of Options and Issue of Ordinary Shares
(b) Sale of Ordinary Shares
(a) Exercise price of \$17.21 per Share
(b) \$72,105

<div>Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i></div> <div>Whether relevant interests were aquired or disposed of during a closed period:</div> <div>Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:</div> <div>Date of the prior written clearance (if any):</div>	<div>(a) Cancellation of 37,622 Options and issue of 8,159 Ordinary Shares (b) 3,300 Ordinary Shares</div>
<div>Summary of other relevant interests after acquisition or disposal:</div>	
<div>Class of quoted financial products:</div> <div>Nature of relevant interest:</div> <div><i>For that relevant interest, -</i></div>	<div>Performance Share Rights</div> <div>Beneficial</div>
<div>Number held in class:</div> <div>Current registered holder(s):</div> <div><i>For a derivative relevant interest, -</i></div>	<div>58,850</div> <div>Andrew Robert Donald Somervell</div>
<div>Type of derivative:</div> <div>Details of derivative,-</div> <div>The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):</div> <div>A statement as to whether the derivative is cash settled or physically settled:</div> <div>Maturity date of the derivative (if any):</div> <div>Expiry date of the derivative (if any):</div> <div>The price's specified terms (if any):</div> <div>Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:</div> <div><i>For that derivative relevant interest, -</i></div> <div>Parties to the derivative:</div> <div>If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:</div>	
<div>Certification</div> <div>I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.</div> <div>Signature of director or officer:</div> <div>Date of signature:</div> <div>or</div> <div>Signature of person authorised to sign on behalf of director or officer:</div> <div>Date of signature:</div> <div>Name and title of authorised person:</div>	<div></div> <div></div> <div>Raelene Leonard</div> <div>29 September 2023</div> <div>Raelene Leonard, Company Secretary</div>



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
29 September 2023
13 September 2023

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Lewis George Gradon
Fisher & Paykel Healthcare Corporation Limited
Chief Executive Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):
For that relevant interest:
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

(a) Options to acquire Ordinary Shares
(b) Ordinary Shares
Beneficial
(a) 524,339 Options
(b) 562,351 Ordinary Shares
(a) 385,512 Options
(b) 578,460 Ordinary Shares
(a) Lewis George Gradon
(b) Lewis George Gradon; Gradon Family Trust
(a) Lewis George Gradon
(b) Lewis George Gradon; Gradon Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

Details of affected derivative:

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative:

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Two

Details of transactions requiring disclosure:

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):

(a) 26 September 2023
(b) 27 September 2023
(a) Cancellation of Options and Issue of Ordinary Shares
(b) Sale of Ordinary Shares

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details:</i>
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):

(a) Exercise price of \$17.21 per Share (b) \$303,493.71
(a) Cancellation of 138,827 Options and issue of 30,109 Ordinary Shares (b) 14,000 Ordinary Shares

Summary of other relevant interests after acquisition or disposal

Class of quoted financial products:
Nature of relevant interest:
<i>For that relevant interest:</i>
Number held in class:
Current registered holder(s):
<i>For a derivative relevant interest:</i>
Type of derivative:
Details of derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest:</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Performance Share Rights
Beneficial
197,786
Lewis George Gradon

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Raelene Leonard
29 September 2023
Raelene Leonard, Company Secretary



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
29 September 2023
13 September 2023

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Paul Nigel Shearer
Fisher & Paykel Healthcare Corporation Limited
Vice President - Sales & Marketing

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):
For that relevant interest-
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

(a) Options to acquire Ordinary Shares
(b) Ordinary Shares
Beneficial
(a) 260,522 Options
(b) 384,968 Ordinary Shares
(a) 194,686 Options
(b) 399,246 Ordinary Shares
(a) Paul Nigel Shearer
(b) Paul Nigel Shearer, Shearer Family Trust
(a) Paul Nigel Shearer
(b) Paul Nigel Shearer, Shearer Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative,-</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:
Details of transactions requiring disclosure-
Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

One
26 September 2023
Cancellation of Options and Issue of Ordinary Shares
Exercise price of \$17.21 per Share

